Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia, Myeloid

Interventions: Drug: Lenalidomide

First Posted Date: 2015-09-02

Last Posted Date: 2020-01-07

Lead Sponsor: Celgene

Target Recruit Count: 17

Registration Number: NCT02538965

Locations: 🇺🇸
Children's Hospital, Birmingham, Alabama, United States
🇺🇸
Miller Children's Hospital, Long Beach, California, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States

and more 59 locations

Lenalidomide Maintenance in Plasma Cell Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2015-09-02

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT02538198

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage III Follicular Lymphoma
Ann Arbor Stage III Marginal Zone Lymphoma
Ann Arbor Stage IV Follicular Lymphoma
Ann Arbor Stage IV Marginal Zone Lymphoma
CD20 Positive
Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2015-08-25

Last Posted Date: 2023-09-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT02532257

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Lenalidomide
Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2015-08-20

Last Posted Date: 2022-11-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT02529852

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Study of Lenalidomide for Adult Histiocyte Disorders

Phase 2

Active, not recruiting

Conditions: Langerhans Cell Histiocytosis (LCH)
Histiocytoses Erdheim-chester Disease
Histiocytic Sarcoma (HS)

Interventions: Drug: Lenalidomide

First Posted Date: 2015-08-14

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02523040

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lenalidomide

First Posted Date: 2015-08-13

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT02521714

Locations: 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Clarithromycin
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-08-06

Last Posted Date: 2023-06-05

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 12

Registration Number: NCT02516696

Locations: 🇺🇸
University of Colorado - Anschutz Cancer Center, Aurora, Colorado, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Phase 3

Active, not recruiting

Conditions: Solitary Osseous Plasmacytoma

Interventions: Drug: ixazomib
Drug: lenalidomide
Drug: dexamethasone
Drug: zoledronic acid

First Posted Date: 2015-08-05

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 11

Registration Number: NCT02516423

Locations: 🇺🇸
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare-Galesburg, Galesburg, Illinois, United States

and more 385 locations

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Phase 1

Completed

Conditions: Plasma Cell Myeloma

Interventions: Drug: lenalidomide
Drug: bortezomib
Drug: cyclophosphamide
Drug: dexamethasone
Drug: isatuximab SAR650984

First Posted Date: 2015-07-31

Last Posted Date: 2024-01-29

Lead Sponsor: Sanofi

Target Recruit Count: 90

Registration Number: NCT02513186

Locations: 🇫🇷
Investigational Site Number : 250003, Pierre Benite, France
🇫🇷
Investigational Site Number : 250002, Nantes Cedex 01, France
🇫🇷
Investigational Site Number : 250001, TOULOUSE Cedex 9, France

and more 9 locations

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: elotuzumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2015-07-13

Last Posted Date: 2021-09-10

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 564

Registration Number: NCT02495922

Locations: 🇩🇪
Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II, Villingen-Schwenningen, Germany
🇩🇪
Rems-Murr-Klinikum gGmbH Winnenden, Winnenden, Germany
🇩🇪
Studienzentrum Aschaffenburg, Aschaffenburg, Germany

and more 64 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy